Kenvue misses quarterly estimates as inflation, tariffs squeeze margins

Kimberly-Clark said it will consolidate 6,000 applications and more than 15 ERP systems as it nears completion of its Kenvue acquisition. On an earnings call, COO Russell Torres cited a three-year plan targeting $1.9 million in savings and identified over $600 million of savings, with system integration and supply chain and commercial integration as key drivers.

U.S. stocks opened mixed as investors digested earnings and economic data. AppLovin (APP) fell over 20% after Q2 revenue of $1.924B missed estimates. Datadog (DDOG) dropped over 18% on weaker bookings and guidance. SpaceX (SPCX) rose about 2.5% after a lockup expiry. Western Digital (WDC) slid 11% on margin outlook; Fiserv (FI) and Kenvue (KVUE) also fell.

Kenvue (NYSE:KVUE) shares fell about 2% after its Q2 results narrowly missed Wall Street expectations. Adjusted diluted EPS was $0.31 vs $0.32 expected, and revenue was $3.96B vs $3.97B. Net sales rose 3%, but margins declined, with gross margin at 58.2% vs 58.9% a year earlier. Kenvue cited inflation, tariffs and FX and gave no forward guidance due to a planned Kimberly-Clark combination.

Kenvue Inc. (KVUE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q226earningspressrelease.htm EX-99.1 Document Kenvue Reports Second Quarter 2026 Results • Delivered Third Consecutive Quarter of Net and Organic Sales 1 Growth • Net Sales Increased 3.0%; Organic Sales Increased 1.6% • Diluted EPS Increased 9% to $0.24; Adjusted Dilute

The FDA approved an OTC pain reliever combining acetaminophen and naproxen sodium, marketed by Kenvue as Tylenol with Naproxen. Kenvue says it starts working within 30 minutes and lasts up to 12 hours, and cites eight studies showing better relief than either ingredient alone. The FDA allows use for temporary relief of minor aches and pains in adults and children 12+.

Nasdaq sees best day in over a month as Microsoft breathes life back into AI trade By Jonathan Stempel NEW YORK, July 30 (Reuters) - A federal appeals court on Thursday revived portions of nationwide litigation in which consumers accused drugmakers such as Procter & Gamble and retailers such as CVS of selling billions of dollars of over-the-counter decongestants that didn’t work. The litigation comprised about 100 lawsuits filed after a U.S.